相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies
G. I. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors
Mark Andrew Dickson et al.
INVESTIGATIONAL NEW DRUGS (2011)
Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Timothy J. Guzi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Guidelines for accurate EC50/IC50 estimation
J. L. Sebaugh
PHARMACEUTICAL STATISTICS (2011)
A Phase I Study of Flavopiridol in Combination With Gemcitabine and Irinotecan in Patients With Metastatic Cancer
Houman M. Fekrazad et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Peter J. Houghton et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer
Richard D. Carvajal et al.
PANCREATOLOGY (2009)
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Jan J. Molenaar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review
Beth A. Christian et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1
Shogo Kobayashi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
Tomas Frgala et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A phase I study of flavopiridol and docetaxel
Basil F. El-Rayes et al.
INVESTIGATIONAL NEW DRUGS (2006)
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo
C Graham et al.
CLINICAL CANCER RESEARCH (2006)
Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: A Children's Oncology Group Study
JA Whitlock et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
JE Karp et al.
CLINICAL CANCER RESEARCH (2005)
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models
JK Peterson et al.
CLINICAL CANCER RESEARCH (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points
KC Bible et al.
CLINICAL CANCER RESEARCH (2005)
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
MA Shah et al.
CLINICAL CANCER RESEARCH (2005)
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies
NLM Liem et al.
BLOOD (2004)
Proliferation of cancer cells despite CDK2 inhibition
O Tetsu et al.
CANCER CELL (2003)
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status
LR Kelland
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
分享论文
